Podcast Episode 2: Heart Failure Management in Patients with Diabetes for Endocrinologists, Primary Care Physicians, and Noncardiologist Clinicians: Focus on SGLT2 Inhibitors.
{"title":"Podcast Episode 2: Heart Failure Management in Patients with Diabetes for Endocrinologists, Primary Care Physicians, and Noncardiologist Clinicians: Focus on SGLT2 Inhibitors.","authors":"Nihar R Desai, Silvio E Inzucchi, Eugene E Wright","doi":"10.1007/s13300-026-01856-6","DOIUrl":null,"url":null,"abstract":"<p><p>Heart failure is a major complication of type 2 diabetes and patients with type 2 diabetes often have to manage multiple comorbid conditions that increase the risk of heart failure, such as hypertension, obesity, chronic kidney disease, and hyperlipidemia. Therefore, management of cardiovascular risk factors through lifestyle modifications and pharmacological intervention is fundamental to prevent the progression of heart failure in patients with diabetes. Hospitalization is common in patients with heart failure, and hospitalizations represent the largest component of direct medical costs for heart failure. Therapies that reduce the burden of hospitalization for heart failure are greatly needed. In this podcast series of three episodes, a cardiovascular specialist, an endocrinologist, and a primary care physician will provide practical guidance for primary care physicians on optimal identification and management of heart failure in patients with diabetes. In this second episode in the series, we give an overview of the tools available to clinicians to reduce the risk of heart failure progression in patients with early-stage heart failure. This includes the discussion of lifestyle modifications as well as the cardiovascular benefits of sodium-glucose co-transporter 2 inhibitors and other medications used at the intersection of diabetes and heart failure. Podcast available for this article.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"807-814"},"PeriodicalIF":4.2000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13253893/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13300-026-01856-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Heart failure is a major complication of type 2 diabetes and patients with type 2 diabetes often have to manage multiple comorbid conditions that increase the risk of heart failure, such as hypertension, obesity, chronic kidney disease, and hyperlipidemia. Therefore, management of cardiovascular risk factors through lifestyle modifications and pharmacological intervention is fundamental to prevent the progression of heart failure in patients with diabetes. Hospitalization is common in patients with heart failure, and hospitalizations represent the largest component of direct medical costs for heart failure. Therapies that reduce the burden of hospitalization for heart failure are greatly needed. In this podcast series of three episodes, a cardiovascular specialist, an endocrinologist, and a primary care physician will provide practical guidance for primary care physicians on optimal identification and management of heart failure in patients with diabetes. In this second episode in the series, we give an overview of the tools available to clinicians to reduce the risk of heart failure progression in patients with early-stage heart failure. This includes the discussion of lifestyle modifications as well as the cardiovascular benefits of sodium-glucose co-transporter 2 inhibitors and other medications used at the intersection of diabetes and heart failure. Podcast available for this article.
期刊介绍：
Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
